SES Enters Exclusive Agreement With ENTEK Membranes, A Global Technology Leader In Battery Separator Materials

SES Holdings Pte. Ltd (“SES”) and ENTEK Membranes LLC announced that they have entered into an exclusive supply agreement for innovative separator materials in the development and production of high-energy Li-Metal rechargeable batteries. Both headquartered in the US with global presence, SES and ENTEK share a vision that is not limited by geography, but that is to power the future of electric transportation with ENTEK materials and SES batteries.

Recommended AI News: Aqua Security Achieves AWS Graviton Ready Designation

In July 2021, SES announced plans to list on the New York Stock Exchange (NYSE) through a merger with Ivanhoe Capital Acquisition Corp. (NYSE: IVAN) (“Ivanhoe”). Upon the closing of the transaction, the combined company will be listed on the NYSE under the new ticker symbol “SES”.

Dr. Rick Pekala, ENTEK Membranes Chief Technology Officer commented, “We are delighted to be partnering with SES, a pioneer in Lithium-Metal rechargeable battery technology and production. We are honored that SES has rewarded our collaborative commitment to the development of SES’s ground-breaking technological achievements in next-generation EV Lithium-Metal batteries in this way.”

Yongkyu Son, SES’ Chief Technology Officer stated, “We are really honored to make this commitment with ENTEK Membranes. Scaling production is always a concern when you bring a new product to market and the supply agreement with Entek Membranes helps us reduce supply chain issues while ensuring superior cycle life in our Lithium-Metal batteries. Supply chain disruption is a major consideration for auto makers as they look to put modern technologies in their cars, especially in the compressed timeframes that the market is demanding. SES is well positioned to fully commercialize its next generation hybrid Li-Metal battery technology and build Giga-scale battery production.

Recommended AI News: Gilead And AWS Collaborate On Development And Delivery Of New Medicines For Patients

[To share your insights with us, please write to sghosh@martechseries.com]